nodes	percent_of_prediction	percent_of_DWPC	metapath
Nedocromil—FPR1—digestive system—pancreatic cancer	0.016	0.211	CbGeAlD
Nedocromil—PTGDR—digestive system—pancreatic cancer	0.0152	0.199	CbGeAlD
Nedocromil—HSP90AA1—gall bladder—pancreatic cancer	0.0148	0.194	CbGeAlD
Nedocromil—HSP90AA1—islet of Langerhans—pancreatic cancer	0.0097	0.127	CbGeAlD
Nedocromil—CYSLTR1—pancreas—pancreatic cancer	0.00786	0.103	CbGeAlD
Nedocromil—HSP90AA1—pancreas—pancreatic cancer	0.00682	0.0895	CbGeAlD
Nedocromil—HSP90AA1—digestive system—pancreatic cancer	0.00582	0.0764	CbGeAlD
Nedocromil—Pneumonia—Erlotinib—pancreatic cancer	0.00208	0.00842	CcSEcCtD
Nedocromil—Conjunctivitis—Erlotinib—pancreatic cancer	0.00201	0.00813	CcSEcCtD
Nedocromil—Sinusitis—Tamoxifen—pancreatic cancer	0.00196	0.00794	CcSEcCtD
Nedocromil—Bronchitis—Sunitinib—pancreatic cancer	0.00193	0.00781	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Sunitinib—pancreatic cancer	0.00187	0.00755	CcSEcCtD
Nedocromil—Pharyngitis—Tamoxifen—pancreatic cancer	0.00187	0.00754	CcSEcCtD
Nedocromil—Visual impairment—Tamoxifen—pancreatic cancer	0.00181	0.00732	CcSEcCtD
Nedocromil—Pneumonia—Sunitinib—pancreatic cancer	0.0018	0.00729	CcSEcCtD
Nedocromil—Influenza—Gemcitabine—pancreatic cancer	0.00161	0.00652	CcSEcCtD
Nedocromil—Rash erythematous—Epirubicin—pancreatic cancer	0.00161	0.0065	CcSEcCtD
Nedocromil—Dysgeusia—Tamoxifen—pancreatic cancer	0.0016	0.00647	CcSEcCtD
Nedocromil—Otitis media—Epirubicin—pancreatic cancer	0.00158	0.00639	CcSEcCtD
Nedocromil—Eosinophilia—Fluorouracil—pancreatic cancer	0.00157	0.00635	CcSEcCtD
Nedocromil—Feeling hot—Epirubicin—pancreatic cancer	0.00157	0.00634	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Irinotecan—pancreatic cancer	0.00154	0.00622	CcSEcCtD
Nedocromil—Stinging—Epirubicin—pancreatic cancer	0.00152	0.00614	CcSEcCtD
Nedocromil—Dysphonia—Epirubicin—pancreatic cancer	0.0015	0.00605	CcSEcCtD
Nedocromil—Rash erythematous—Doxorubicin—pancreatic cancer	0.00149	0.00601	CcSEcCtD
Nedocromil—Pneumonia—Irinotecan—pancreatic cancer	0.00149	0.006	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Fluorouracil—pancreatic cancer	0.00147	0.00596	CcSEcCtD
Nedocromil—Leukopenia—Tamoxifen—pancreatic cancer	0.00146	0.00592	CcSEcCtD
Nedocromil—Otitis media—Doxorubicin—pancreatic cancer	0.00146	0.00591	CcSEcCtD
Nedocromil—Feeling hot—Doxorubicin—pancreatic cancer	0.00145	0.00586	CcSEcCtD
Nedocromil—Pneumonia—Gemcitabine—pancreatic cancer	0.00145	0.00585	CcSEcCtD
Nedocromil—Cough—Tamoxifen—pancreatic cancer	0.00143	0.00577	CcSEcCtD
Nedocromil—Pneumonia—Fluorouracil—pancreatic cancer	0.00142	0.00575	CcSEcCtD
Nedocromil—Cough—Erlotinib—pancreatic cancer	0.00141	0.00571	CcSEcCtD
Nedocromil—Stinging—Doxorubicin—pancreatic cancer	0.00141	0.00568	CcSEcCtD
Nedocromil—Chest pain—Tamoxifen—pancreatic cancer	0.00139	0.00563	CcSEcCtD
Nedocromil—Dysphonia—Doxorubicin—pancreatic cancer	0.00138	0.00559	CcSEcCtD
Nedocromil—Chest pain—Erlotinib—pancreatic cancer	0.00138	0.00557	CcSEcCtD
Nedocromil—Conjunctivitis—Fluorouracil—pancreatic cancer	0.00138	0.00556	CcSEcCtD
Nedocromil—Dysgeusia—Sunitinib—pancreatic cancer	0.00137	0.00554	CcSEcCtD
Nedocromil—Viral infection—Epirubicin—pancreatic cancer	0.00136	0.00551	CcSEcCtD
Nedocromil—Dry mouth—Tamoxifen—pancreatic cancer	0.00136	0.0055	CcSEcCtD
Nedocromil—Cough increased—Epirubicin—pancreatic cancer	0.00134	0.00543	CcSEcCtD
Nedocromil—Rhinitis—Irinotecan—pancreatic cancer	0.00133	0.00537	CcSEcCtD
Nedocromil—Sinusitis—Fluorouracil—pancreatic cancer	0.00133	0.00536	CcSEcCtD
Nedocromil—Rhinitis—Gemcitabine—pancreatic cancer	0.00129	0.00523	CcSEcCtD
Nedocromil—Pharyngitis—Gemcitabine—pancreatic cancer	0.00128	0.00518	CcSEcCtD
Nedocromil—Visual impairment—Irinotecan—pancreatic cancer	0.00128	0.00516	CcSEcCtD
Nedocromil—Rhinitis—Fluorouracil—pancreatic cancer	0.00127	0.00514	CcSEcCtD
Nedocromil—Viral infection—Doxorubicin—pancreatic cancer	0.00126	0.0051	CcSEcCtD
Nedocromil—Pharyngitis—Fluorouracil—pancreatic cancer	0.00126	0.00509	CcSEcCtD
Nedocromil—Leukopenia—Sunitinib—pancreatic cancer	0.00125	0.00507	CcSEcCtD
Nedocromil—Cough increased—Doxorubicin—pancreatic cancer	0.00124	0.00503	CcSEcCtD
Nedocromil—Cough—Sunitinib—pancreatic cancer	0.00122	0.00494	CcSEcCtD
Nedocromil—Chest pain—Sunitinib—pancreatic cancer	0.00119	0.00482	CcSEcCtD
Nedocromil—Dyspnoea—Tamoxifen—pancreatic cancer	0.00119	0.00481	CcSEcCtD
Nedocromil—Dyspnoea—Erlotinib—pancreatic cancer	0.00118	0.00476	CcSEcCtD
Nedocromil—Dyspepsia—Tamoxifen—pancreatic cancer	0.00118	0.00475	CcSEcCtD
Nedocromil—Dry mouth—Sunitinib—pancreatic cancer	0.00117	0.00471	CcSEcCtD
Nedocromil—Dyspepsia—Erlotinib—pancreatic cancer	0.00116	0.0047	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.00115	0.00466	CcSEcCtD
Nedocromil—Fatigue—Tamoxifen—pancreatic cancer	0.00115	0.00465	CcSEcCtD
Nedocromil—Pain—Tamoxifen—pancreatic cancer	0.00114	0.00461	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.00114	0.00461	CcSEcCtD
Nedocromil—Fatigue—Erlotinib—pancreatic cancer	0.00114	0.0046	CcSEcCtD
Nedocromil—Pain—Erlotinib—pancreatic cancer	0.00113	0.00456	CcSEcCtD
Nedocromil—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.00109	0.00441	CcSEcCtD
Nedocromil—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.00108	0.00436	CcSEcCtD
Nedocromil—Urticaria—Tamoxifen—pancreatic cancer	0.00106	0.00429	CcSEcCtD
Nedocromil—Abdominal pain—Tamoxifen—pancreatic cancer	0.00106	0.00426	CcSEcCtD
Nedocromil—Abdominal pain—Erlotinib—pancreatic cancer	0.00104	0.00422	CcSEcCtD
Nedocromil—Body temperature increased—Erlotinib—pancreatic cancer	0.00104	0.00422	CcSEcCtD
Nedocromil—Leukopenia—Irinotecan—pancreatic cancer	0.00103	0.00417	CcSEcCtD
Nedocromil—Pneumonia—Docetaxel—pancreatic cancer	0.00103	0.00415	CcSEcCtD
Nedocromil—Dyspnoea—Sunitinib—pancreatic cancer	0.00102	0.00412	CcSEcCtD
Nedocromil—Cough—Irinotecan—pancreatic cancer	0.00101	0.00407	CcSEcCtD
Nedocromil—Dyspepsia—Sunitinib—pancreatic cancer	0.00101	0.00407	CcSEcCtD
Nedocromil—Leukopenia—Gemcitabine—pancreatic cancer	0.00101	0.00407	CcSEcCtD
Nedocromil—Eczema—Epirubicin—pancreatic cancer	0.000994	0.00402	CcSEcCtD
Nedocromil—Conjunctivitis—Docetaxel—pancreatic cancer	0.000993	0.00401	CcSEcCtD
Nedocromil—Leukopenia—Fluorouracil—pancreatic cancer	0.00099	0.004	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000987	0.00399	CcSEcCtD
Nedocromil—Fatigue—Sunitinib—pancreatic cancer	0.000986	0.00398	CcSEcCtD
Nedocromil—Hypersensitivity—Tamoxifen—pancreatic cancer	0.000984	0.00397	CcSEcCtD
Nedocromil—Cough—Gemcitabine—pancreatic cancer	0.000981	0.00396	CcSEcCtD
Nedocromil—Pain—Sunitinib—pancreatic cancer	0.000978	0.00395	CcSEcCtD
Nedocromil—Asthenia—Tamoxifen—pancreatic cancer	0.000958	0.00387	CcSEcCtD
Nedocromil—Chest pain—Gemcitabine—pancreatic cancer	0.000957	0.00387	CcSEcCtD
Nedocromil—Asthenia—Erlotinib—pancreatic cancer	0.000948	0.00383	CcSEcCtD
Nedocromil—Anaphylactic shock—Irinotecan—pancreatic cancer	0.000942	0.00381	CcSEcCtD
Nedocromil—Chest pain—Fluorouracil—pancreatic cancer	0.000941	0.0038	CcSEcCtD
Nedocromil—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.000935	0.00378	CcSEcCtD
Nedocromil—Eczema—Doxorubicin—pancreatic cancer	0.00092	0.00372	CcSEcCtD
Nedocromil—Rhinitis—Docetaxel—pancreatic cancer	0.000919	0.00371	CcSEcCtD
Nedocromil—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.000918	0.00371	CcSEcCtD
Nedocromil—Diarrhoea—Tamoxifen—pancreatic cancer	0.000914	0.00369	CcSEcCtD
Nedocromil—Pharyngitis—Docetaxel—pancreatic cancer	0.00091	0.00368	CcSEcCtD
Nedocromil—Body temperature increased—Sunitinib—pancreatic cancer	0.000904	0.00365	CcSEcCtD
Nedocromil—Abdominal pain—Sunitinib—pancreatic cancer	0.000904	0.00365	CcSEcCtD
Nedocromil—Diarrhoea—Erlotinib—pancreatic cancer	0.000904	0.00365	CcSEcCtD
Nedocromil—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.000902	0.00365	CcSEcCtD
Nedocromil—Visual impairment—Docetaxel—pancreatic cancer	0.000883	0.00357	CcSEcCtD
Nedocromil—Dizziness—Tamoxifen—pancreatic cancer	0.000883	0.00357	CcSEcCtD
Nedocromil—Dizziness—Erlotinib—pancreatic cancer	0.000874	0.00353	CcSEcCtD
Nedocromil—Vomiting—Tamoxifen—pancreatic cancer	0.000849	0.00343	CcSEcCtD
Nedocromil—Hypersensitivity—Sunitinib—pancreatic cancer	0.000843	0.0034	CcSEcCtD
Nedocromil—Rash—Tamoxifen—pancreatic cancer	0.000842	0.0034	CcSEcCtD
Nedocromil—Dermatitis—Tamoxifen—pancreatic cancer	0.000841	0.0034	CcSEcCtD
Nedocromil—Vomiting—Erlotinib—pancreatic cancer	0.00084	0.00339	CcSEcCtD
Nedocromil—Dyspnoea—Irinotecan—pancreatic cancer	0.00084	0.00339	CcSEcCtD
Nedocromil—Headache—Tamoxifen—pancreatic cancer	0.000837	0.00338	CcSEcCtD
Nedocromil—Rash—Erlotinib—pancreatic cancer	0.000833	0.00337	CcSEcCtD
Nedocromil—Dermatitis—Erlotinib—pancreatic cancer	0.000832	0.00336	CcSEcCtD
Nedocromil—Dyspepsia—Irinotecan—pancreatic cancer	0.000829	0.00335	CcSEcCtD
Nedocromil—Headache—Erlotinib—pancreatic cancer	0.000828	0.00334	CcSEcCtD
Nedocromil—Asthenia—Sunitinib—pancreatic cancer	0.000821	0.00332	CcSEcCtD
Nedocromil—Dyspnoea—Gemcitabine—pancreatic cancer	0.000818	0.00331	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000813	0.00329	CcSEcCtD
Nedocromil—Fatigue—Irinotecan—pancreatic cancer	0.000812	0.00328	CcSEcCtD
Nedocromil—Pain—Irinotecan—pancreatic cancer	0.000806	0.00325	CcSEcCtD
Nedocromil—Dyspnoea—Fluorouracil—pancreatic cancer	0.000804	0.00325	CcSEcCtD
Nedocromil—Dyspepsia—Fluorouracil—pancreatic cancer	0.000794	0.00321	CcSEcCtD
Nedocromil—Nausea—Tamoxifen—pancreatic cancer	0.000793	0.0032	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000792	0.0032	CcSEcCtD
Nedocromil—Fatigue—Gemcitabine—pancreatic cancer	0.000791	0.0032	CcSEcCtD
Nedocromil—Pain—Gemcitabine—pancreatic cancer	0.000785	0.00317	CcSEcCtD
Nedocromil—Nausea—Erlotinib—pancreatic cancer	0.000785	0.00317	CcSEcCtD
Nedocromil—Diarrhoea—Sunitinib—pancreatic cancer	0.000783	0.00316	CcSEcCtD
Nedocromil—Dysgeusia—Docetaxel—pancreatic cancer	0.000781	0.00316	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000779	0.00315	CcSEcCtD
Nedocromil—Influenza—Epirubicin—pancreatic cancer	0.000772	0.00312	CcSEcCtD
Nedocromil—Pain—Fluorouracil—pancreatic cancer	0.000772	0.00312	CcSEcCtD
Nedocromil—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.00077	0.00311	CcSEcCtD
Nedocromil—Eosinophilia—Epirubicin—pancreatic cancer	0.000765	0.00309	CcSEcCtD
Nedocromil—Dizziness—Sunitinib—pancreatic cancer	0.000756	0.00306	CcSEcCtD
Nedocromil—Abdominal pain—Irinotecan—pancreatic cancer	0.000745	0.00301	CcSEcCtD
Nedocromil—Body temperature increased—Irinotecan—pancreatic cancer	0.000745	0.00301	CcSEcCtD
Nedocromil—Bronchitis—Epirubicin—pancreatic cancer	0.000743	0.003	CcSEcCtD
Nedocromil—Vomiting—Sunitinib—pancreatic cancer	0.000727	0.00294	CcSEcCtD
Nedocromil—Body temperature increased—Gemcitabine—pancreatic cancer	0.000725	0.00293	CcSEcCtD
Nedocromil—Rash—Sunitinib—pancreatic cancer	0.000721	0.00291	CcSEcCtD
Nedocromil—Dermatitis—Sunitinib—pancreatic cancer	0.00072	0.00291	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.000718	0.0029	CcSEcCtD
Nedocromil—Urticaria—Fluorouracil—pancreatic cancer	0.000717	0.0029	CcSEcCtD
Nedocromil—Headache—Sunitinib—pancreatic cancer	0.000716	0.00289	CcSEcCtD
Nedocromil—Influenza—Doxorubicin—pancreatic cancer	0.000715	0.00289	CcSEcCtD
Nedocromil—Leukopenia—Docetaxel—pancreatic cancer	0.000714	0.00289	CcSEcCtD
Nedocromil—Body temperature increased—Fluorouracil—pancreatic cancer	0.000713	0.00288	CcSEcCtD
Nedocromil—Eosinophilia—Doxorubicin—pancreatic cancer	0.000708	0.00286	CcSEcCtD
Nedocromil—Cough—Docetaxel—pancreatic cancer	0.000696	0.00281	CcSEcCtD
Nedocromil—Hypersensitivity—Irinotecan—pancreatic cancer	0.000694	0.0028	CcSEcCtD
Nedocromil—Pneumonia—Epirubicin—pancreatic cancer	0.000693	0.0028	CcSEcCtD
Nedocromil—Bronchitis—Doxorubicin—pancreatic cancer	0.000687	0.00278	CcSEcCtD
Nedocromil—Chest pain—Docetaxel—pancreatic cancer	0.000679	0.00274	CcSEcCtD
Nedocromil—Nausea—Sunitinib—pancreatic cancer	0.000679	0.00274	CcSEcCtD
Nedocromil—Asthenia—Irinotecan—pancreatic cancer	0.000676	0.00273	CcSEcCtD
Nedocromil—Conjunctivitis—Epirubicin—pancreatic cancer	0.000669	0.0027	CcSEcCtD
Nedocromil—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000665	0.00269	CcSEcCtD
Nedocromil—Dry mouth—Docetaxel—pancreatic cancer	0.000664	0.00268	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000664	0.00268	CcSEcCtD
Nedocromil—Asthenia—Gemcitabine—pancreatic cancer	0.000658	0.00266	CcSEcCtD
Nedocromil—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000651	0.00263	CcSEcCtD
Nedocromil—Sinusitis—Epirubicin—pancreatic cancer	0.000646	0.00261	CcSEcCtD
Nedocromil—Diarrhoea—Irinotecan—pancreatic cancer	0.000645	0.0026	CcSEcCtD
Nedocromil—Pneumonia—Doxorubicin—pancreatic cancer	0.000641	0.00259	CcSEcCtD
Nedocromil—Diarrhoea—Gemcitabine—pancreatic cancer	0.000628	0.00254	CcSEcCtD
Nedocromil—Dizziness—Irinotecan—pancreatic cancer	0.000623	0.00252	CcSEcCtD
Nedocromil—Rhinitis—Epirubicin—pancreatic cancer	0.00062	0.0025	CcSEcCtD
Nedocromil—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000619	0.0025	CcSEcCtD
Nedocromil—Diarrhoea—Fluorouracil—pancreatic cancer	0.000617	0.00249	CcSEcCtD
Nedocromil—Pharyngitis—Epirubicin—pancreatic cancer	0.000614	0.00248	CcSEcCtD
Nedocromil—Vomiting—Irinotecan—pancreatic cancer	0.000599	0.00242	CcSEcCtD
Nedocromil—Sinusitis—Doxorubicin—pancreatic cancer	0.000598	0.00242	CcSEcCtD
Nedocromil—Dizziness—Fluorouracil—pancreatic cancer	0.000597	0.00241	CcSEcCtD
Nedocromil—Visual impairment—Epirubicin—pancreatic cancer	0.000596	0.00241	CcSEcCtD
Nedocromil—Rash—Irinotecan—pancreatic cancer	0.000594	0.0024	CcSEcCtD
Nedocromil—Dermatitis—Irinotecan—pancreatic cancer	0.000593	0.0024	CcSEcCtD
Nedocromil—Headache—Irinotecan—pancreatic cancer	0.00059	0.00238	CcSEcCtD
Nedocromil—Vomiting—Gemcitabine—pancreatic cancer	0.000583	0.00236	CcSEcCtD
Nedocromil—Dyspnoea—Docetaxel—pancreatic cancer	0.000581	0.00235	CcSEcCtD
Nedocromil—Rash—Gemcitabine—pancreatic cancer	0.000579	0.00234	CcSEcCtD
Nedocromil—Dermatitis—Gemcitabine—pancreatic cancer	0.000578	0.00234	CcSEcCtD
Nedocromil—Headache—Gemcitabine—pancreatic cancer	0.000575	0.00232	CcSEcCtD
Nedocromil—Vomiting—Fluorouracil—pancreatic cancer	0.000574	0.00232	CcSEcCtD
Nedocromil—Rhinitis—Doxorubicin—pancreatic cancer	0.000574	0.00232	CcSEcCtD
Nedocromil—Dyspepsia—Docetaxel—pancreatic cancer	0.000573	0.00232	CcSEcCtD
Nedocromil—Rash—Fluorouracil—pancreatic cancer	0.000569	0.0023	CcSEcCtD
Nedocromil—Dermatitis—Fluorouracil—pancreatic cancer	0.000568	0.0023	CcSEcCtD
Nedocromil—Pharyngitis—Doxorubicin—pancreatic cancer	0.000568	0.00229	CcSEcCtD
Nedocromil—Headache—Fluorouracil—pancreatic cancer	0.000565	0.00228	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000562	0.00227	CcSEcCtD
Nedocromil—Fatigue—Docetaxel—pancreatic cancer	0.000561	0.00227	CcSEcCtD
Nedocromil—Nausea—Irinotecan—pancreatic cancer	0.00056	0.00226	CcSEcCtD
Nedocromil—Pain—Docetaxel—pancreatic cancer	0.000557	0.00225	CcSEcCtD
Nedocromil—Visual impairment—Doxorubicin—pancreatic cancer	0.000551	0.00223	CcSEcCtD
Nedocromil—Nausea—Gemcitabine—pancreatic cancer	0.000545	0.0022	CcSEcCtD
Nedocromil—Nausea—Fluorouracil—pancreatic cancer	0.000536	0.00217	CcSEcCtD
Nedocromil—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000533	0.00215	CcSEcCtD
Nedocromil—Dysgeusia—Epirubicin—pancreatic cancer	0.000527	0.00213	CcSEcCtD
Nedocromil—Body temperature increased—Docetaxel—pancreatic cancer	0.000515	0.00208	CcSEcCtD
Nedocromil—Abdominal pain—Docetaxel—pancreatic cancer	0.000515	0.00208	CcSEcCtD
Nedocromil—Dysgeusia—Doxorubicin—pancreatic cancer	0.000488	0.00197	CcSEcCtD
Nedocromil—Leukopenia—Epirubicin—pancreatic cancer	0.000482	0.00195	CcSEcCtD
Nedocromil—Hypersensitivity—Docetaxel—pancreatic cancer	0.00048	0.00194	CcSEcCtD
Nedocromil—Cough—Epirubicin—pancreatic cancer	0.00047	0.0019	CcSEcCtD
Nedocromil—Asthenia—Docetaxel—pancreatic cancer	0.000467	0.00189	CcSEcCtD
Nedocromil—Chest pain—Epirubicin—pancreatic cancer	0.000458	0.00185	CcSEcCtD
Nedocromil—Dry mouth—Epirubicin—pancreatic cancer	0.000448	0.00181	CcSEcCtD
Nedocromil—Leukopenia—Doxorubicin—pancreatic cancer	0.000446	0.0018	CcSEcCtD
Nedocromil—Diarrhoea—Docetaxel—pancreatic cancer	0.000446	0.0018	CcSEcCtD
Nedocromil—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000439	0.00177	CcSEcCtD
Nedocromil—Cough—Doxorubicin—pancreatic cancer	0.000435	0.00176	CcSEcCtD
Nedocromil—Dizziness—Docetaxel—pancreatic cancer	0.000431	0.00174	CcSEcCtD
Nedocromil—Chest pain—Doxorubicin—pancreatic cancer	0.000424	0.00171	CcSEcCtD
Nedocromil—Dry mouth—Doxorubicin—pancreatic cancer	0.000415	0.00168	CcSEcCtD
Nedocromil—Vomiting—Docetaxel—pancreatic cancer	0.000414	0.00167	CcSEcCtD
Nedocromil—Rash—Docetaxel—pancreatic cancer	0.000411	0.00166	CcSEcCtD
Nedocromil—Dermatitis—Docetaxel—pancreatic cancer	0.00041	0.00166	CcSEcCtD
Nedocromil—Headache—Docetaxel—pancreatic cancer	0.000408	0.00165	CcSEcCtD
Nedocromil—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000406	0.00164	CcSEcCtD
Nedocromil—Dyspnoea—Epirubicin—pancreatic cancer	0.000392	0.00158	CcSEcCtD
Nedocromil—Nausea—Docetaxel—pancreatic cancer	0.000387	0.00156	CcSEcCtD
Nedocromil—Dyspepsia—Epirubicin—pancreatic cancer	0.000387	0.00156	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000379	0.00153	CcSEcCtD
Nedocromil—Fatigue—Epirubicin—pancreatic cancer	0.000379	0.00153	CcSEcCtD
Nedocromil—Pain—Epirubicin—pancreatic cancer	0.000376	0.00152	CcSEcCtD
Nedocromil—Dyspnoea—Doxorubicin—pancreatic cancer	0.000362	0.00146	CcSEcCtD
Nedocromil—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000359	0.00145	CcSEcCtD
Nedocromil—Dyspepsia—Doxorubicin—pancreatic cancer	0.000358	0.00145	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000351	0.00142	CcSEcCtD
Nedocromil—Fatigue—Doxorubicin—pancreatic cancer	0.00035	0.00142	CcSEcCtD
Nedocromil—Urticaria—Epirubicin—pancreatic cancer	0.000349	0.00141	CcSEcCtD
Nedocromil—Pain—Doxorubicin—pancreatic cancer	0.000348	0.0014	CcSEcCtD
Nedocromil—Abdominal pain—Epirubicin—pancreatic cancer	0.000347	0.0014	CcSEcCtD
Nedocromil—Body temperature increased—Epirubicin—pancreatic cancer	0.000347	0.0014	CcSEcCtD
Nedocromil—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000332	0.00134	CcSEcCtD
Nedocromil—Hypersensitivity—Epirubicin—pancreatic cancer	0.000324	0.00131	CcSEcCtD
Nedocromil—Urticaria—Doxorubicin—pancreatic cancer	0.000323	0.0013	CcSEcCtD
Nedocromil—Body temperature increased—Doxorubicin—pancreatic cancer	0.000321	0.0013	CcSEcCtD
Nedocromil—Abdominal pain—Doxorubicin—pancreatic cancer	0.000321	0.0013	CcSEcCtD
Nedocromil—Asthenia—Epirubicin—pancreatic cancer	0.000315	0.00127	CcSEcCtD
Nedocromil—Diarrhoea—Epirubicin—pancreatic cancer	0.000301	0.00121	CcSEcCtD
Nedocromil—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000299	0.00121	CcSEcCtD
Nedocromil—Asthenia—Doxorubicin—pancreatic cancer	0.000292	0.00118	CcSEcCtD
Nedocromil—Dizziness—Epirubicin—pancreatic cancer	0.00029	0.00117	CcSEcCtD
Nedocromil—Vomiting—Epirubicin—pancreatic cancer	0.000279	0.00113	CcSEcCtD
Nedocromil—Diarrhoea—Doxorubicin—pancreatic cancer	0.000278	0.00112	CcSEcCtD
Nedocromil—Rash—Epirubicin—pancreatic cancer	0.000277	0.00112	CcSEcCtD
Nedocromil—Dermatitis—Epirubicin—pancreatic cancer	0.000277	0.00112	CcSEcCtD
Nedocromil—Headache—Epirubicin—pancreatic cancer	0.000275	0.00111	CcSEcCtD
Nedocromil—Dizziness—Doxorubicin—pancreatic cancer	0.000269	0.00109	CcSEcCtD
Nedocromil—Nausea—Epirubicin—pancreatic cancer	0.000261	0.00105	CcSEcCtD
Nedocromil—Vomiting—Doxorubicin—pancreatic cancer	0.000258	0.00104	CcSEcCtD
Nedocromil—Rash—Doxorubicin—pancreatic cancer	0.000256	0.00104	CcSEcCtD
Nedocromil—Dermatitis—Doxorubicin—pancreatic cancer	0.000256	0.00103	CcSEcCtD
Nedocromil—Headache—Doxorubicin—pancreatic cancer	0.000255	0.00103	CcSEcCtD
Nedocromil—Nausea—Doxorubicin—pancreatic cancer	0.000241	0.000975	CcSEcCtD
Nedocromil—CYSLTR1—Signaling Pathways—STK11—pancreatic cancer	0.000107	0.000158	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—KRAS—pancreatic cancer	0.000107	0.000158	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—KDR—pancreatic cancer	0.000106	0.000156	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SHH—pancreatic cancer	0.000106	0.000156	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NOTCH4—pancreatic cancer	0.000105	0.000155	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IAPP—pancreatic cancer	0.000104	0.000154	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—KRAS—pancreatic cancer	0.000104	0.000154	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—CCND1—pancreatic cancer	0.000104	0.000153	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CD44—pancreatic cancer	0.000102	0.000151	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—PIK3CA—pancreatic cancer	0.000102	0.00015	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—NFKBIA—pancreatic cancer	0.000101	0.000149	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—PIK3CD—pancreatic cancer	0.000101	0.000149	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PTCH1—pancreatic cancer	0.0001	0.000148	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PTHLH—pancreatic cancer	0.0001	0.000148	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—NOTCH1—pancreatic cancer	9.97e-05	0.000147	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—CTNNB1—pancreatic cancer	9.91e-05	0.000146	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—PIK3CB—pancreatic cancer	9.87e-05	0.000146	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—PIK3CB—pancreatic cancer	9.86e-05	0.000146	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—PIK3CA—pancreatic cancer	9.82e-05	0.000145	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—GCG—pancreatic cancer	9.77e-05	0.000144	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PIK3CG—pancreatic cancer	9.75e-05	0.000144	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—NRAS—pancreatic cancer	9.75e-05	0.000144	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—MMP9—pancreatic cancer	9.71e-05	0.000144	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—PIK3CB—pancreatic cancer	9.65e-05	0.000143	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—EGF—pancreatic cancer	9.64e-05	0.000142	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—SMAD4—pancreatic cancer	9.61e-05	0.000142	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—PIK3CB—pancreatic cancer	9.52e-05	0.000141	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—CXCL8—pancreatic cancer	9.47e-05	0.00014	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—HRAS—pancreatic cancer	9.41e-05	0.000139	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—HES1—pancreatic cancer	9.38e-05	0.000139	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—SMAD4—pancreatic cancer	9.37e-05	0.000139	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—CXCL8—pancreatic cancer	9.27e-05	0.000137	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—CCND1—pancreatic cancer	9.26e-05	0.000137	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—STK11—pancreatic cancer	9.19e-05	0.000136	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SST—pancreatic cancer	9.17e-05	0.000136	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—HES1—pancreatic cancer	9.15e-05	0.000135	CbGpPWpGaD
Nedocromil—FPR1—GPCR downstream signaling—AKT1—pancreatic cancer	9.15e-05	0.000135	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—CXCL8—pancreatic cancer	9.15e-05	0.000135	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—HRAS—pancreatic cancer	9.09e-05	0.000134	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—CASP3—pancreatic cancer	9.07e-05	0.000134	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—JAG1—pancreatic cancer	8.97e-05	0.000133	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—SRC—pancreatic cancer	8.95e-05	0.000132	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NOTCH3—pancreatic cancer	8.93e-05	0.000132	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—EGFR—pancreatic cancer	8.88e-05	0.000131	CbGpPWpGaD
Nedocromil—PTGDR—GPCR downstream signaling—AKT1—pancreatic cancer	8.84e-05	0.000131	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—HRAS—pancreatic cancer	8.83e-05	0.000131	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—CCND1—pancreatic cancer	8.82e-05	0.00013	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—PIK3CB—pancreatic cancer	8.76e-05	0.00013	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—CASP3—pancreatic cancer	8.76e-05	0.000129	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—CTNNB1—pancreatic cancer	8.75e-05	0.000129	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—CTNNB1—pancreatic cancer	8.74e-05	0.000129	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—VEGFA—pancreatic cancer	8.72e-05	0.000129	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—STAT3—pancreatic cancer	8.64e-05	0.000128	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—NRAS—pancreatic cancer	8.61e-05	0.000127	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PIK3CD—pancreatic cancer	8.57e-05	0.000127	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—MMP9—pancreatic cancer	8.57e-05	0.000127	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—BCL2L1—pancreatic cancer	8.55e-05	0.000126	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—PTEN—pancreatic cancer	8.53e-05	0.000126	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—CCND1—pancreatic cancer	8.52e-05	0.000126	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—PTEN—pancreatic cancer	8.52e-05	0.000126	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—TSC2—pancreatic cancer	8.49e-05	0.000126	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.49e-05	0.000126	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CNR1—pancreatic cancer	8.46e-05	0.000125	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—CTNNB1—pancreatic cancer	8.44e-05	0.000125	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—CXCL8—pancreatic cancer	8.42e-05	0.000125	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—KRAS—pancreatic cancer	8.39e-05	0.000124	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—AKT1—pancreatic cancer	8.31e-05	0.000123	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—MYC—pancreatic cancer	8.31e-05	0.000123	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—MMP9—pancreatic cancer	8.27e-05	0.000122	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—PTEN—pancreatic cancer	8.23e-05	0.000122	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—TERT—pancreatic cancer	8.22e-05	0.000122	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—GCG—pancreatic cancer	8.17e-05	0.000121	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—AKT1—pancreatic cancer	8.02e-05	0.000119	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TERT—pancreatic cancer	8.02e-05	0.000119	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—TGFB1—pancreatic cancer	8.01e-05	0.000118	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—SRC—pancreatic cancer	7.91e-05	0.000117	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—TYMS—pancreatic cancer	7.9e-05	0.000117	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—SRC—pancreatic cancer	7.9e-05	0.000117	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—HIF1A—pancreatic cancer	7.86e-05	0.000116	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—EGFR—pancreatic cancer	7.85e-05	0.000116	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—TSC2—pancreatic cancer	7.84e-05	0.000116	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—AGTR1—pancreatic cancer	7.79e-05	0.000115	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—NFKBIA—pancreatic cancer	7.75e-05	0.000115	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—PIK3CA—pancreatic cancer	7.71e-05	0.000114	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—VEGFA—pancreatic cancer	7.69e-05	0.000114	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—STK11—pancreatic cancer	7.68e-05	0.000114	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—APOE—pancreatic cancer	7.67e-05	0.000113	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—HIF1A—pancreatic cancer	7.67e-05	0.000113	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TSC2—pancreatic cancer	7.65e-05	0.000113	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—SRC—pancreatic cancer	7.63e-05	0.000113	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—STAT3—pancreatic cancer	7.62e-05	0.000113	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—NRAS—pancreatic cancer	7.61e-05	0.000113	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—NRAS—pancreatic cancer	7.6e-05	0.000112	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—APOE—pancreatic cancer	7.49e-05	0.000111	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—TNF—pancreatic cancer	7.47e-05	0.000111	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PIK3CB—pancreatic cancer	7.47e-05	0.00011	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—VEGFA—pancreatic cancer	7.43e-05	0.00011	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—MYC—pancreatic cancer	7.43e-05	0.00011	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—EGF—pancreatic cancer	7.42e-05	0.00011	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—KRAS—pancreatic cancer	7.41e-05	0.00011	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—STAT3—pancreatic cancer	7.36e-05	0.000109	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—NRAS—pancreatic cancer	7.34e-05	0.000109	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—KDR—pancreatic cancer	7.34e-05	0.000108	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CXCL8—pancreatic cancer	7.18e-05	0.000106	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—HRAS—pancreatic cancer	7.13e-05	0.000105	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—NOTCH1—pancreatic cancer	7.08e-05	0.000105	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—MYC—pancreatic cancer	7.08e-05	0.000105	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—TGFB1—pancreatic cancer	7.06e-05	0.000104	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NFKBIA—pancreatic cancer	6.98e-05	0.000103	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—AKT1—pancreatic cancer	6.93e-05	0.000103	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—EGFR—pancreatic cancer	6.93e-05	0.000102	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—EGFR—pancreatic cancer	6.92e-05	0.000102	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NOTCH1—pancreatic cancer	6.91e-05	0.000102	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CDH1—pancreatic cancer	6.9e-05	0.000102	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CASP3—pancreatic cancer	6.87e-05	0.000102	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—EGF—pancreatic cancer	6.85e-05	0.000101	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—MYC—pancreatic cancer	6.84e-05	0.000101	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—TGFB1—pancreatic cancer	6.82e-05	0.000101	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CG—pancreatic cancer	6.76e-05	9.99e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—NRAS—pancreatic cancer	6.76e-05	9.99e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SMAD4—pancreatic cancer	6.73e-05	9.95e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CCND1—pancreatic cancer	6.69e-05	9.89e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—EGFR—pancreatic cancer	6.69e-05	9.89e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—EGF—pancreatic cancer	6.68e-05	9.88e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CTNNB1—pancreatic cancer	6.62e-05	9.79e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3CD—pancreatic cancer	6.59e-05	9.75e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—HES1—pancreatic cancer	6.57e-05	9.71e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—KRAS—pancreatic cancer	6.55e-05	9.68e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—KRAS—pancreatic cancer	6.54e-05	9.67e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MMP9—pancreatic cancer	6.49e-05	9.6e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PTEN—pancreatic cancer	6.45e-05	9.54e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—APOE—pancreatic cancer	6.43e-05	9.5e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—KRAS—pancreatic cancer	6.32e-05	9.34e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—HRAS—pancreatic cancer	6.3e-05	9.32e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—AKT1—pancreatic cancer	6.3e-05	9.31e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—EGFR—pancreatic cancer	6.16e-05	9.1e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—TP53—pancreatic cancer	6.1e-05	9.02e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3CD—pancreatic cancer	6.09e-05	9e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—PIK3CA—pancreatic cancer	6.02e-05	8.9e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—PIK3CA—pancreatic cancer	6.01e-05	8.88e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—SRC—pancreatic cancer	5.99e-05	8.85e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CD—pancreatic cancer	5.94e-05	8.78e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—PIK3CA—pancreatic cancer	5.88e-05	8.7e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—VEGFA—pancreatic cancer	5.83e-05	8.62e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—KRAS—pancreatic cancer	5.82e-05	8.6e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—TP53—pancreatic cancer	5.81e-05	8.59e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—PIK3CA—pancreatic cancer	5.8e-05	8.58e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CG—pancreatic cancer	5.8e-05	8.58e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—STAT3—pancreatic cancer	5.77e-05	8.54e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—NRAS—pancreatic cancer	5.76e-05	8.52e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TERT—pancreatic cancer	5.76e-05	8.51e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3CB—pancreatic cancer	5.75e-05	8.5e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—TP53—pancreatic cancer	5.61e-05	8.3e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PPARG—pancreatic cancer	5.6e-05	8.28e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—HRAS—pancreatic cancer	5.57e-05	8.23e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—AKT1—pancreatic cancer	5.56e-05	8.23e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—HRAS—pancreatic cancer	5.56e-05	8.22e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—HIF1A—pancreatic cancer	5.51e-05	8.14e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TSC2—pancreatic cancer	5.49e-05	8.12e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—APOE—pancreatic cancer	5.37e-05	7.95e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—HRAS—pancreatic cancer	5.37e-05	7.94e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MYC—pancreatic cancer	5.36e-05	7.93e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—TGFB1—pancreatic cancer	5.35e-05	7.91e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—PIK3CA—pancreatic cancer	5.34e-05	7.9e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3CB—pancreatic cancer	5.31e-05	7.85e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—KDR—pancreatic cancer	5.27e-05	7.79e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PTGS2—pancreatic cancer	5.26e-05	7.78e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—EGFR—pancreatic cancer	5.25e-05	7.76e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CB—pancreatic cancer	5.18e-05	7.66e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CD—pancreatic cancer	5.1e-05	7.54e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CTNNB1—pancreatic cancer	5.1e-05	7.54e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NFKBIA—pancreatic cancer	5.01e-05	7.41e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CXCL8—pancreatic cancer	4.98e-05	7.36e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PTEN—pancreatic cancer	4.97e-05	7.34e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NOTCH1—pancreatic cancer	4.96e-05	7.33e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—KRAS—pancreatic cancer	4.96e-05	7.33e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—HRAS—pancreatic cancer	4.94e-05	7.31e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—AKT1—pancreatic cancer	4.91e-05	7.27e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—AKT1—pancreatic cancer	4.91e-05	7.26e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CG—pancreatic cancer	4.85e-05	7.17e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—AKT1—pancreatic cancer	4.81e-05	7.11e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EGF—pancreatic cancer	4.79e-05	7.09e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CASP3—pancreatic cancer	4.76e-05	7.04e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—AKT1—pancreatic cancer	4.74e-05	7.01e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CTNNB1—pancreatic cancer	4.71e-05	6.96e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CCND1—pancreatic cancer	4.64e-05	6.85e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—SRC—pancreatic cancer	4.61e-05	6.81e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CTNNB1—pancreatic cancer	4.59e-05	6.79e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PTEN—pancreatic cancer	4.59e-05	6.78e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PIK3CA—pancreatic cancer	4.55e-05	6.73e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MMP9—pancreatic cancer	4.5e-05	6.65e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PTEN—pancreatic cancer	4.47e-05	6.62e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CB—pancreatic cancer	4.44e-05	6.57e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—STAT3—pancreatic cancer	4.44e-05	6.57e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—NRAS—pancreatic cancer	4.43e-05	6.55e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—TP53—pancreatic cancer	4.41e-05	6.51e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PTGS2—pancreatic cancer	4.4e-05	6.51e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—AKT1—pancreatic cancer	4.36e-05	6.45e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CD—pancreatic cancer	4.26e-05	6.3e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—SRC—pancreatic cancer	4.25e-05	6.29e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—HRAS—pancreatic cancer	4.21e-05	6.23e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—SRC—pancreatic cancer	4.15e-05	6.14e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—STAT3—pancreatic cancer	4.1e-05	6.06e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—NRAS—pancreatic cancer	4.09e-05	6.05e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—VEGFA—pancreatic cancer	4.04e-05	5.98e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—EGFR—pancreatic cancer	4.04e-05	5.97e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—STAT3—pancreatic cancer	4e-05	5.92e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NRAS—pancreatic cancer	3.99e-05	5.9e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PTEN—pancreatic cancer	3.84e-05	5.68e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—KRAS—pancreatic cancer	3.81e-05	5.64e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MYC—pancreatic cancer	3.81e-05	5.64e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—TGFB1—pancreatic cancer	3.8e-05	5.62e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—EGFR—pancreatic cancer	3.73e-05	5.51e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—AKT1—pancreatic cancer	3.72e-05	5.5e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MYC—pancreatic cancer	3.72e-05	5.5e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CB—pancreatic cancer	3.72e-05	5.5e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TGFB1—pancreatic cancer	3.71e-05	5.48e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—EGFR—pancreatic cancer	3.64e-05	5.38e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CXCL8—pancreatic cancer	3.57e-05	5.28e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—KRAS—pancreatic cancer	3.52e-05	5.21e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3CA—pancreatic cancer	3.5e-05	5.18e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—KRAS—pancreatic cancer	3.44e-05	5.08e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CASP3—pancreatic cancer	3.42e-05	5.05e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CCND1—pancreatic cancer	3.33e-05	4.92e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CTNNB1—pancreatic cancer	3.29e-05	4.87e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—HRAS—pancreatic cancer	3.24e-05	4.79e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3CA—pancreatic cancer	3.24e-05	4.78e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MMP9—pancreatic cancer	3.23e-05	4.78e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PTEN—pancreatic cancer	3.21e-05	4.75e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CA—pancreatic cancer	3.16e-05	4.67e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TP53—pancreatic cancer	3.05e-05	4.51e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—HRAS—pancreatic cancer	2.99e-05	4.43e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SRC—pancreatic cancer	2.98e-05	4.4e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—HRAS—pancreatic cancer	2.92e-05	4.32e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—VEGFA—pancreatic cancer	2.9e-05	4.29e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—STAT3—pancreatic cancer	2.87e-05	4.25e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NRAS—pancreatic cancer	2.87e-05	4.24e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—AKT1—pancreatic cancer	2.86e-05	4.23e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CA—pancreatic cancer	2.71e-05	4.01e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MYC—pancreatic cancer	2.67e-05	3.95e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TGFB1—pancreatic cancer	2.66e-05	3.94e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—AKT1—pancreatic cancer	2.64e-05	3.91e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EGFR—pancreatic cancer	2.61e-05	3.86e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—AKT1—pancreatic cancer	2.58e-05	3.81e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—KRAS—pancreatic cancer	2.47e-05	3.65e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CA—pancreatic cancer	2.27e-05	3.35e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—AKT1—pancreatic cancer	2.21e-05	3.27e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TP53—pancreatic cancer	2.19e-05	3.24e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—HRAS—pancreatic cancer	2.1e-05	3.1e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—AKT1—pancreatic cancer	1.85e-05	2.74e-05	CbGpPWpGaD
